Related Experiment Videos
Cholinergic mediation in dermorphin-induced growth hormone secretion in man
Hormone Research
|January 1, 1986
Summary
Pirenzepine blocks dermorphin-induced growth hormone (GH) release by acting on the central cholinergic system. However, it does not affect prolactin (PRL) release, indicating a specific role for cholinergic pathways in GH regulation.
Area of Science:
- Neuroendocrinology
- Pharmacology
Background:
- Cholinergic muscarinic antagonists play a role in regulating hormone secretion.
- Dermorphin is a potent stimulator of growth hormone (GH) and prolactin (PRL) release.
Purpose of the Study:
- To investigate the role of the cholinergic system in mediating the GH and PRL response to dermorphin in humans.
- To determine the specific effects of pirenzepine on dermorphin-induced hormone release.
Main Methods:
- Seven healthy males were administered dermorphin to assess its effects on GH and PRL levels.
- Pirenzepine, a cholinergic muscarinic antagonist, was administered to evaluate its impact on dermorphin's hormonal effects.
Main Results:
- Dermorphin significantly increased both GH and PRL levels.
- Pirenzepine completely inhibited the GH-releasing effect of dermorphin.
- Pirenzepine did not alter the PRL-releasing activity of dermorphin.
Conclusions:
- The GH-releasing action of dermorphin in humans is mediated through the central cholinergic nervous system.
- Cholinergic pathways are specifically involved in the regulation of GH release by dermorphin, but not PRL release.